@article{2b5c4d3c4c504b5991fd4c00538d473b,
title = "Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease?",
author = "Sumithira Vasu and Samantha Jaglowski",
note = "Funding Information: Financial disclosure: Boehringer Ingelheim (Germany), Pfizer (New York, USA), Stemline Therapeutics (New York, USA), Kite therapeutics (Santa Monica, CA, USA), Novartis (Basel, Switzerland), Unum Therapeutics (Cambridge, MA) and AmGen (Thousand Oaks, CA, USA). Dr. Vasu is supported in part by National Heart, Lung and Blood Institute , Bethesda, MD grant 5 UG1 HL109322-09 . Funding Information: Financial disclosure: Boehringer Ingelheim (Germany), Pfizer (New York, USA), Stemline Therapeutics (New York, USA), Kite therapeutics (Santa Monica, CA, USA), Novartis (Basel, Switzerland), Unum Therapeutics (Cambridge, MA) and AmGen (Thousand Oaks, CA, USA). Dr. Vasu is supported in part by National Heart, Lung and Blood Institute, Bethesda, MD grant 5 UG1 HL109322-09. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page XX. Funding Information: Financial disclosure: Boehringer Ingelheim (Germany), Pfizer (New York, USA), Stemline Therapeutics (New York, USA), Kite therapeutics (Santa Monica, CA, USA), Novartis (Basel, Switzerland), Unum Therapeutics (Cambridge, MA) and AmGen (Thousand Oaks, CA, USA). Dr. Vasu is supported in part by National Heart, Lung and Blood Institute, Bethesda, MD grant 5 UG1 HL109322-09. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page e190.",
year = "2019",
month = jun,
doi = "10.1016/j.bbmt.2019.04.009",
language = "English",
volume = "25",
pages = "e189--e190",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
number = "6",
}